* RenovoRx Inc reported a quarterly adjusted loss of 31 cents per share for the quarter ended in December, lower than the same quarter last year, when the company reported EPS of -23 cents. The mean expectation of three analysts for the quarter was for a loss of 30 cents per share. Wall Street expected results to range from -31 cents to -30 cents per share.
* Reported revenue was zero; analysts expected zero.
* RenovoRx Inc's reported EPS for the quarter was a loss of 31 cents.
* The company reported a quarterly loss of $3.23 million.
* RenovoRx Inc shares had held steady so far this quarter and lost 41.5% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 0.5% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "buy"
Wall Street's median 12-month price target for RenovoRx Inc is $4.00 This summary was machine generated from LSEG data April 1 at 10:14 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2023 -0.30 -0.31 Missed
Sep. 30 2023 -0.30 -0.13 Beat
Jun. 30 2023 -0.25 -0.31 Missed
Mar. 31 2023 -0.25 -0.36 Missed
Comments